Accessibility Menu
 
Metagenomi Therapeutics logo

Metagenomi Therapeutics

(NASDAQ) MGX

Current Price$1.31
Market Cap$49.66M
Since IPO (2024)-87%
5 YearN/A
1 Year-14%
1 Month-15%

Metagenomi Therapeutics Financials at a Glance

Market Cap

$49.66M

Revenue (TTM)

$25.21M

Net Income (TTM)

$87.87M

EPS (TTM)

$-2.36

P/E Ratio

-0.56

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$1.31

Volume

4,148

Open

$1.36

Previous Close

$1.31

Daily Range

$1.31 - $1.36

52-Week Range

$1.23 - $3.95

MGX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Metagenomi Therapeutics

Industry

Biotechnology

Employees

119

CEO

Jian Irish, PhD, MBA

Headquarters

Emeryville, 94608, US

MGX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

-4%

Net Income Margin

-3%

Return on Equity

-45%

Return on Capital

-48%

Return on Assets

-40%

Earnings Yield

-1.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$49.66M

Shares Outstanding

37.62M

Volume

4.15K

Short Interest

0.00%

Avg. Volume

267.36K

Financials (TTM)

Gross Profit

$19.89M

Operating Income

$96.01M

EBITDA

$90.70M

Operating Cash Flow

$88.89M

Capital Expenditure

$574.00K

Free Cash Flow

$89.47M

Cash & ST Invst.

$160.80M

Total Debt

$40.66M

Metagenomi Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$3.91M

-59.3%

Gross Profit

$2.61M

-72.8%

Gross Margin

66.76%

N/A

Market Cap

$49.66M

N/A

Market Cap/Employee

$245.84K

N/A

Employees

202

N/A

Net Income

$22.53M

+3.7%

EBITDA

$23.07M

-20.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$120.14M

-40.7%

Accounts Receivable

$305.00K

-75.7%

Inventory

$0.00

N/A

Long Term Debt

$34.63M

-13.8%

Short Term Debt

$6.03M

+7.7%

Return on Assets

-39.74%

N/A

Return on Invested Capital

-48.45%

N/A

Free Cash Flow

$23.63M

+11.2%

Operating Cash Flow

$23.55M

+10.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IFRXInflaRx N.V.
$0.91-1.95%
ATYRaTyr Pharma, Inc.
$0.75-5.13%
DTILPrecision BioSciences, Inc.
$6.02-7.95%
QNCXQuince Therapeutics, Inc.
$0.09-6.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About MGX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.